Inventor
FARDIS MARIA
US27 patents
⚠️ This page may combine multiple inventors who share the name “FARDIS MARIA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
GILEAD SCIENCES INC
17 patentsUS9139604B2Sep 22, 2015
Antiviral phosphonate analogs
GILEAD SCIENCES INC42 citations97
US8871785B2Oct 28, 2014
Antiviral phosphonate analogs
GILEAD SCIENCES INC49 citations97
US8022083B2Sep 20, 2011
Antiviral phosphonate analogs
GILEAD SCIENCES INC46 citations97
US7645747B2Jan 12, 2010
Therapeutic phosphonate compounds
GILEAD SCIENCES INC60 citations97
US7452901B2Nov 18, 2008
Anti-cancer phosphonate analogs
GILEAD SCIENCES INC70 citations97
US7470724B2Dec 30, 2008
Phosphonate compounds having immuno-modulatory activity
GILEAD SCIENCES INC23 citations92
US7429565B2Sep 30, 2008
Antiviral phosphonate analogs
GILEAD SCIENCES INC25 citations92
US7427636B2Sep 23, 2008
Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
GILEAD SCIENCES INC21 citations92
US7417055B2Aug 26, 2008
Kinase inhibitory phosphonate analogs
GILEAD SCIENCES INC37 citations92
US7407965B2Aug 5, 2008
Phosphonate analogs for treating metabolic diseases
GILEAD SCIENCES INC27 citations92
US7893264B2Feb 22, 2011
Antiviral phosphinate compounds
GILEAD SCIENCES INC15 citations91
US7649015B2Jan 19, 2010
Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds
GILEAD SCIENCES INC19 citations91
US7432261B2Oct 7, 2008
Anti-inflammatory phosphonate compounds
GILEAD SCIENCES INC24 citations91
US7432273B2Oct 7, 2008
Phosphonate analogs of antimetabolites
GILEAD SCIENCES INC9 citations84
US7427624B2Sep 23, 2008
Purine nucleoside phosphorylase inhibitory phosphonate compounds
GILEAD SCIENCES INC12 citations84
US7253180B2Aug 7, 2007
Pre-organized tricyclic integrase inhibitor compounds
GILEAD SCIENCES INC17 citations82
US7432272B2Oct 7, 2008
Antiviral analogs
GILEAD SCIENCES INC2 citations63
IOVANCE BIOTHERAPEUTICS INC
4 patentsUS11819517B2Nov 21, 2023
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
IOVANCE BIOTHERAPEUTICS INC18 citations94
US11433097B2Sep 6, 2022
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
IOVANCE BIOTHERAPEUTICS INC25 citations94
US12343380B2Jul 1, 2025
Expansion of TILs utilizing AKT pathways inhibitors
IOVANCE BIOTHERAPEUTICS INC2 citations74
US12553029B2Feb 17, 2026
Treatment of NSCLC patients with tumor infiltrating lymphocyte therapies
IOVANCE BIOTHERAPEUTICS INC2 citations66